79 results about "Renal blood flow" patented technology

Intravascular devices are delivered to the aorta percutaneously via the femoral artery. The devices are anchored within the vasculature in the region of the renal artery ostia. These embodiments function to increase the flow of blood from the aorta to the renal arteries, thus delivering a higher relative percentage of the blood flowing through the aorta to the kidneys. The elevation in blood low to the kidneys improves the natural removal of excess fluids from the body. In one embodiment, the device is a diverter element positionable upstream of the renal artery ostia. In another embodiment, the device is a flow restrictor positionable downstream of the ostia to cause an elevation is pressure upstream of the ostia.

There is disclosed a porous emboli deflector for preventing cerebral emboli while maintaining cerebral blood flow during an endovascular or open surgical procedure. The device prevents the entrance of emboli of a size able to cause stroke (such as greater than 100 microns) from entering either the right or left common carotid arteries, and / or the right or left vertebral arteries by deflecting emboli downstream of these vessels. The device can be placed prior to any manipulation of the heart or aorta allowing maximal protection of the brain during the index procedure. The deflector has a low profile within the aorta which allows sheaths, catheters, or wires used in the index procedure to pass. Also disclosed are methods for insertion and removal of the deflector.

The present invention provides a treatment for enhancing the ability of the body to heal wounds. A topical cream is described which improves blood flow by the transdermal delivery of the nitric oxide precursor L-Arginine either alone or with an adjunct, theophylline. The delivery of the active agents is accomplished by use of a vehicle which contains a hostile biophysical environment which is also hostile to hydrogen bond formation.

Apparatus for modifying a property of a brain of a patient is provided, including one or more electrodes (7), adapted to be applied to a site selected from a group of sites consisting of: a sphenopalatine ganglion (SPG) (6) of the patient and a neural tract originating in or leading to the SPG. A control unit (8) is adapted to drive the one or more electrodes to apply a current to the site capable of inducing (a) an increase in permeability of a blood-brain barrier (BBB) of the patient, (b) a change in cerebral blood flow of the patient, and / or (c) an inhibition of parasympathetic activity of the SPG.

Methods and apparatus are provided for determining individual vascular responses by employing iontophoresis to deliver vasoactive compounds to local area and determining resultant changes in blood flow by measuring changes in skin temperature as a correlate of local blood flow. The invention further provides methods and apparatus for assessing vascular reactivity in individuals under ambulatory conditions and relating stress responses to vascular reactivity.

The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and / or function, removing body fat and / or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline.

A method for increasing cerebral blood flow in a patient. A electrical stimulating device is provided. The electrical stimulating device is applied to the patient at a region adjacent the cervical sympathetic chain, the brain stem, the head, or the sympathetic nervous system. The electrical stimulating device is applied by any route selected from transcutaneous, subcutaneous, and subarachnoid. The electrical stimulating device is activated to stimulate or inhibit nerve impulses of the cervical sympathetic chain, thereby producing vasodilation in the cerebral vasculature, thereby increasing cerebral blood flow. Devices for increasing cerebral blood flow in a patient are also described.

The present invention relates to devices and systems that alter intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform by oscillating the contraction and expansion of a compressible composition within the cranial or spinal cavities such that they increase intracranial capacity. The contraction and expansion of the compressible composition in the oscillating compliance devices can be due to an individual's intracranial pressure, the result of the expansion and compression of a reservoir which is mediated by the contractility of the heart or driven by a pump gaited to a biorhythm. The invention also relates to methods for protecting an individual's brain from abnormal arterial pulsations and for altering an individual's cerebral blood flow using the devices and systems of the invention. The oscillating compliance devices can be used to treat several diseases and / or conditions characterized by altered / abnormal intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform, including hydrocephalus, stroke, dementia and migraine headaches, vasospasms, congestive heart failure, cardiopulmonary bypass or carotid endarterectomy.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and / or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

A method of estimating cerebral blood flow includes obtaining a measure of time-varying blood volume in the head, using an impedance plethysmography (102 and 104), obtaining a measure of time-varying blood volume in the scalp, and using the time-varying blood volume in the head and scalp to estimate cerebral blood flow.

The invention discloses a new traditional Chinese medicine composition for treating liver ascites symptoms and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared from the following medicine components: cassia twig, tuckahoe, rhizoma alismatis, Plantain seed, fiveleaf akebia, Lobelia, mulberry bark, climbing fern spore, broom cypress fruit, lysimachia, talcum, notopterygium root, ledebouriella root, acanthopanax bark, orientvine, cinnamon, clove, pangolin, dried orange peer, immature bitter orange, nut grass, rhubarb, hemlock parsley, magnolia bark, Chinese yam, white atractylodes rhizome, semen raphani, japanese sweetflag, bush-cherry seed, angelica glabra, Evodia rutaecarpa, galangal, allium macrostemon, Semen Euryales, pyrrosia lingua, ricepaperplant and oriental wormwood. The traditional Chinese medicine composition can be prepared into any commonly-used oral preparation by using the conventional traditional Chinese medicine preparation method. The invention can obviously improve the symptoms of abdominal distention, ascites, difficulty in walking, and probable obvious diaphragm elevation with expiratory dyspnea and exomphalocele before the ocurrence of ascites. Some patients possibly have the symptoms of hydrothorax, increased portal venous pressure, increased hydrostatic pressure abdominal visceral vessel beds, hypoalbuminemia diseases, excessive lymphogenesis, secondary hyperaldosteronism, reduction of renal blood flow, sodium output and urinary output and the like. The traditional Chinese medicine composition has exact and obvious clinical curative effect and high efficiency. By basically combining edible and pharmaceutical products specified in the national pharmacopoeia, the traditional Chinese medicine composition has the advantages of low cost, no toxic or side effects and the like.

The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and / or its derivatives alone, or optionally in conjunction with an adjunct such as theophylline. The transdermal delivery is effected, in certain embodiments through the means of a hostile biophysical environment, such as that created by a high ionic strength environment. Various pathological states caused by, or occurring in conjunction with, insufficient blood flow, can be treated using the systems and methods of the invention as described herein. In other embodiments, increased blood flow using the systems and methods of the invention may result in enhanced healing, for example, through greater availability of the constituents of the blood. Examples of conditions which may benefit from increased blood flow include, but are not limited to, erectile dysfunction, hair loss, female sexual dissatisfaction, sagging facial or other body tissue, peripheral vascular disease including claudication, neuropathy, skin ulcers, bone healing, wound healing, viral and bacterial infection, and skin grafting.

The invention relates to compositions, such as pharmaceuticals, foods, food additives, or dietary supplements, containing A-type procyanidins, and methods of use thereof, for prophylactic or therapeutic treatment of a human or a veterinary animal to treat or prevent NO-responsive health conditions, treat hypertension, cardiovascular disease, coronary artery disease and / or vascular circulation disorders, prevent or reduce the risk of heart attack, stroke, congestive heart failure and / or kidney failure, or to improve blood flow, for example renal blood flow. The composition may optionally contain an additional NO modulating agent and / or a cardiovascular-protective or therapeutic agent, or may be administered in combination with such an agent.

Hydrogenated pyrido[4,3-b]indoles and pyrido[3,4-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B. in The compounds may find use in therapy, e.g., to (i) reduce blood pressure and / or (ii) promote renal blood flow and / or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

The invention relates to a cervical blood flow detecting device, comprising a collar body with an opening, a probe holder which is rotatably mounted at one end of the collar body and is used for fixedly mounting the probe and an elastic pressing mechanism which is arranged between the probe holder and the collar body and drives the probe holder to be pressed, wherein the probe is mounted on the probe holder and is fixed after finding the target vessel through manual operation, thus removing the defect of unstable signals because of influence of any tiny movement such as tremble of the hand holding the probe, talk and the like. The device has the advantages of ensuring the acquired blood flow signals to be stable, mitigating fatigue of the operators, saving the physical strength of the operators, etc.

The invention relates to a method for noninvasively and quantitatively measuring local blood flows of human organs. The method comprises the following steps of: performing positron emission tomography / fluorodeoxyglucose (PET / H2150) dynamic scanning on a human body, wherein scanned parts are determined according to circumstances; selecting the whole brain or other organs as reference areas as required, or selecting any parts of the brain or other organs as reference areas, and directly applying a formula; determining a relative local blood flow P1 of each part in the brain or other organs, wherein the part is not the same part as a contained area, and the P1 is automatically taken as 1 when the areas are completely overlapped; and performing normalization processing on the whole brain or the whole organs after the value of the relative local blood flow P1 of each part of the selected brain or other organs is solved. By the method, the per-pixels of the analyzed organs can be quantitatively determined, functional images of the local blood flow can be generated and input functions are not needed, so that blood drawing is not needed, and complicated correction is not needed. The method has high accuracy and facilitates practical application.

Disclosed herein are methods and apparatus for diagnosing a disease in the gingival region of an individual, comprising: quantitatively measuring blood flow or changes in blood flow in the gingival region of the individual, potentially comparing these data to that of a healthy subject, and diagnosing the disease based one of more of these quantities.

Endoluminal devices are provided for the treatment of heart failure which include a central body adapted to permit the passage of interatrial blood, at least one anchor attached to the central body adapted to keep the endoluminal device in position within a defect present in the atrial septum of a patient's heart, and at least one control element engaged with the central body in a rotating manner. The rotation of the control element in relation to the central body creates a two-way flow of interatrial blood which allows the reduction of high pressure in the right side and in the left side of the heart.

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the STAT test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate. The test can be administered to a patient having, or suspected of having, Chronic Hepatitis C, Primary Sclerosing Cholangitis (PSC), Non-Alcoholic Fatty Liver Disease (NAFLD), or any chronic liver disease.